Clinical Trial

Real-time Artificial Intelligence-based Speech Enhancement Methods for Hearing Aid Improvement

Study acronym: REFINED
Recruiting
View on ClinicalTrials.gov →
Summary
Individuals with Auditory Neuropathy Spectrum Disorders (ANSD) represent 1-10% of adults with hearing loss. These individuals have little or no benefit from current hearing aids because ANSD is a continuum of hearing impairments due to synaptic or neural dysfunction in the peripheral and central parts of the auditory pathways, which impairs temporal information processing without necessarily affecting auditory sensitivity. There is a need to find ad-hoc denoising methods, based on the expert knowledge of audiologists, to improve the noise comprehension performance of these patients. Implemented denoising methods, based on artificial intelligence, will also greatly benefit more standard hearing loss cases.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-08-02; most recent amendment 2024-03-14.
Status change: Not Yet Recruiting → Recruiting 2024-01-04
Trial Details
NCT Number NCT05985473
Lead Sponsor Institut Pasteur
Conditions Deafness Neurosensory
Enrollment 40 participants
Start Date 2024-03-06
Primary Completion 2026-09-15 (estimated)
Study Completion 2026-09-15 (estimated)
Updated on ClinicalTrials.gov 2024-03-15